RESULTS	Rosiglitazone treated patients also displayed further improvements in glycemic control compared to placebo ( HbA ( 1C ) : 6.4 + or - 0.7 % vs. 7.0 + or - 0.9 % , P < 0.001 ) as well as in several cardiometabolic parameters such as lipids ( HDL-C : 1.16 + or - 0.28 mmol/l vs. 1.06 + or - 0.23 mmol/l , P = 0.003 ) , inflammatory profile ( C-reactive protein : 0.92 mg/l [ 0.51-1 .56 ] vs. 1.37 mg/l [ 0.79-3 .08 ] , P = 0.02 ) , and adiponectin levels ( 11.1 microg/ml [ 8.19-17 .9 ] vs. 4.65 microg/ml [ 3.27-7 .15 ] , P < 0.001 ) .\